Comparison of Specific Antibody, D-Phe-Pro-Arg-CH2Cl and Aprotinin for Prevention of In Vitro Effects of Recombinant Tissue-Type Plasminogen Activator on Haemostasis Parameters

E Seifried; P Tanswell

doi:10.1055/s-0038-1646016

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1987; 58(03): 921-926
DOI: 10.1055/s-0038-1646016

Original Article

Schattauer GmbH Stuttgart

Comparison of Specific Antibody, D-Phe-Pro-Arg-CH₂Cl and Aprotinin for Prevention of In Vitro Effects of Recombinant Tissue-Type Plasminogen Activator on Haemostasis Parameters

E Seifried

^*The Abteilung Innere Medizin III, Universität Ulm, FRG

,

P Tanswell

^**The Department of Biochemistry, Dr. Karl Thomae GmbH, Biberach an der Riss, FRG

› Author Affiliations

Abstract

PDF Download

Summary

In vitro, concentration-dependent effects of rt-PA on a range of coagulation and fibrinolytic assays in thawed plasma samples were investigated. In absence of a fibrinolytic inhibitor, 2 μg rt-PA/ml blood (3.4 μg/ml plasma) caused prolongation of clotting time assays and decreases of plasminogen (to 44% of the control value), fibrinogen (to 27%), α₂-antiplasmin (to 5%), FV (to 67%), FVIII (to 41%) and FXIII (to 16%).

Of three inhibitors tested, a specific polyclonal anti-rt-PA antibody prevented interferences in all fibrinolytic and most clotting assays. D-Phe-Pro-Arg-CH₂Cl (PPACK) enabled correct assays of fibrinogen and fibrinolytic parameters but interfered with coagulometric assays dependent on endogenous thrombin generation. Aprotinin was suitable only for a restricted range of both assay types.

Most in vitro effects were observed only with rt-PA plasma concentrations in excess of therapeutic values. Nevertheless it is concluded that for clinical application, collection of blood samples on either specific antibody or PPACK is essential for a correct assessment of in vivo effects of rt-PA on the haemostatic system in patients undergoing fibrinolytic therapy.

Keywords

rt-PA - Inhibition of in vitro fibrinogenolysis - Coagulation and fibrinolytic assays

PDF (937 kb)

References

References
1 Hoylaerts M, Rijken DC, Lijnen H, Collen D. Kinetics of the activation of plasminogen by human tissue-type plasminogen activator: role of fibrin. J Biol Chem 1982; 257: 2912-2919
2 Collen D, Stassen JM, Marafino BJ, Builder S, de Cock F, Ogez J, Tajiri D, Pennica D, Bennett WF, Salwa J, Hoyng CF. Biological properties of human tissue type plasminogen activator obtained by expression of recombinant DNA in mammalian cells. J Pharmacol Exp Ther 1984; 231: 146-152
3 Verstraete M, Su C AP F, Tanswell P, Feuerer W, Collen D. Pharmacokinetics and effects on fibrinolytic and coagulation parameters of two doses of recombinant tissue-type plasminogen activator in healthy volunteers. Thromb Haemostas 1986; 56: 1-5
4 Verstraete M, Bounameaux H, de Cock F, van de Werf F, Collen D. Pharmacokinetics and systemic fibrinogenolytic effects of recombinant human tissue type plasminogen activator (rt-PA) in humans. J Pharmacol Exp Ther 1985; 235: 506-512
5 Verstraete M. Clinical application of inhibitors of fibrinolysis. Drugs 1985; 29: 236-261
6 Tiefenbrunn AJ, Graor RA, Robison AK, Lucas FV, Hotchkiss A, Sobel BE. Pharmacodynamics of tissue-type plasminogen activator characterized by computer-assisted simulation. Circulation 1986; 73: 1291-1299
7 Holvoet P, Lijnen HR, Collen D. A monoclonal antibody preventing binding of tissue-type plasminogen activator to fibrin: useful to monitor fibrinogen breakdown during t-PA infusion. Blood 1986; 67: 1482-1487
8 Friberger P. Chromogenic peptide substrates: their use for the assay of factors in the fibrinolytic and the plasma kallikrein-kinin systems. Scand J Clin Lab Invest 1982; 42 Suppl. (162) 41-47
9 Philapitsch A, Popov-Cenic S. Pilotuntersuchungen von Inhibitoren. Inhibitionswirkungen und Aktivierbarkeiten in Plasma wahrend der Herz-Lungenmaschine. Verhandlbr. 25. Tagung der deutschen Ar beitsgemeinschaft fur Blutgerinnungsforschung. Schattauer Verlag; 221-232 1981
10 Quick AJ, Stanley-Brown H, Bancroft UM. A study of the coagulation defect in hemophilia and in jaundice. Amer J Med Sci 1935; 190: 501-511
11 Proctor RR, Rapaport SJ. The partial thromboplastin time with kaolin. Amer J Clin Pathol 1961; 36: 212-219
12 Jurgen J. Uber das Verhalten antithrombotischer Substanzen bei Erkrankungen der Leber. Dtsch Arch Klin Med 1952; 200: 67-85
13 Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haemat 1957; 17: 237-246
14 Bohn H, Haupt H. Eine quantitative Bestimmung von FXIII mit Antifaktor XHI-Serum. Thrombos Diathes Haemorrh 1968; 19: 309-315
15 Tanswell P, Zahn G, Seifried E. ELISA for recombinant tissue-type plasminogen activator (rt-PA): development and application to clinical and experimental pharmacokinetics. Proceedings, Chemrawn V Conference (lUPAC/Gesellschaft Deutscher Chemiker). 1986
16 Seifried E, Tanswell P, Su C AP F, Feuerer W, Pindur G, Heimpel H. Recombinant tissue-type plasminogen activator: effects on the coagulation and fibrinolytic system in healthy volunteers. In: Flemostasis, recent advances and new developments in Hemostasiology, 4th Congress, German Society of Thrombosis and Hemostasis 1986. Breddin HK, Bender N, Scharf RE. (Eds) 45-46
17 Lijnen HR, Uytterhoeven M, Collen D. Inhibition of trypsin-like serine proteinases by tripeptide arginyl and lysyl chloromethyl ketones. Thromb Res 1984; 34: 431-437
18 Mohler MA, Refino CJ, Chen SA, Chen AB, Hotchkiss AJ. D-Phe- Pro-Arg-chloromethlyketone: its potential use in inhibiting the formation of in vitro artifacts in blood collected during tissue-type plasminogen activator thrombolytic therapy. Thromb Haemostas 1986; 56: 160-164
19 Garrett ER, Lambert HJ. Pharmacokinetics of trichloroethanol and metabolites and interconversions among variously referenced pharmacokinetic parameters. J Pharmaceut Sci 1973; 62: 550-572